JPS5955830A - 末梢神経系統における興奮伝導の刺戟剤としての医薬組成物 - Google Patents
末梢神経系統における興奮伝導の刺戟剤としての医薬組成物Info
- Publication number
- JPS5955830A JPS5955830A JP16155182A JP16155182A JPS5955830A JP S5955830 A JPS5955830 A JP S5955830A JP 16155182 A JP16155182 A JP 16155182A JP 16155182 A JP16155182 A JP 16155182A JP S5955830 A JPS5955830 A JP S5955830A
- Authority
- JP
- Japan
- Prior art keywords
- muscle
- nerve
- transmission
- pharmaceutical composition
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000005540 biological transmission Effects 0.000 title claims description 11
- 230000002093 peripheral effect Effects 0.000 title claims description 4
- 239000000203 mixture Substances 0.000 title description 19
- 210000003205 muscle Anatomy 0.000 title description 16
- 210000005036 nerve Anatomy 0.000 title description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- 239000000243 solution Substances 0.000 claims description 17
- 210000002460 smooth muscle Anatomy 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 210000003169 central nervous system Anatomy 0.000 claims description 7
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 6
- 239000008024 pharmaceutical diluent Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 2
- 239000012154 double-distilled water Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 description 44
- 150000001875 compounds Chemical class 0.000 description 38
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 20
- 238000011282 treatment Methods 0.000 description 16
- 238000009472 formulation Methods 0.000 description 15
- 206010029240 Neuritis Diseases 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 11
- 229960003980 galantamine Drugs 0.000 description 10
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 10
- OSZNNLWOYWAHSS-UHFFFAOYSA-M neostigmine methyl sulfate Chemical compound COS([O-])(=O)=O.CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 OSZNNLWOYWAHSS-UHFFFAOYSA-M 0.000 description 10
- 229930185790 proserin Natural products 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 206010036105 Polyneuropathy Diseases 0.000 description 8
- 239000000544 cholinesterase inhibitor Substances 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 230000004936 stimulating effect Effects 0.000 description 8
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 7
- 229960004373 acetylcholine Drugs 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 206010028372 Muscular weakness Diseases 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000036473 myasthenia Effects 0.000 description 6
- 102100033639 Acetylcholinesterase Human genes 0.000 description 5
- 108010022752 Acetylcholinesterase Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 229940022698 acetylcholinesterase Drugs 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000002964 excitative effect Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 208000019629 polyneuritis Diseases 0.000 description 5
- 108010053652 Butyrylcholinesterase Proteins 0.000 description 4
- 102100032404 Cholinesterase Human genes 0.000 description 4
- 102000003914 Cholinesterases Human genes 0.000 description 4
- 108090000322 Cholinesterases Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- HJJPJSXJAXAIPN-UHFFFAOYSA-N arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 229940048961 cholinesterase Drugs 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000002232 neuromuscular Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000005923 long-lasting effect Effects 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 208000018360 neuromuscular disease Diseases 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 208000000813 polyradiculoneuropathy Diseases 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 210000003497 sciatic nerve Anatomy 0.000 description 3
- JFJZZMVDLULRGK-URLMMPGGSA-O tubocurarine Chemical compound C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 JFJZZMVDLULRGK-URLMMPGGSA-O 0.000 description 3
- 229960001844 tubocurarine Drugs 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010001541 Akinesia Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 2
- 229960004046 apomorphine Drugs 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000037020 contractile activity Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 210000000256 facial nerve Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000004118 muscle contraction Effects 0.000 description 2
- 239000003158 myorelaxant agent Substances 0.000 description 2
- 210000004126 nerve fiber Anatomy 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000000578 peripheral nerve Anatomy 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- GXFZCDMWGMFGFL-KKXMJGKMSA-N (+)-Tubocurarine chloride hydrochloride Chemical compound [Cl-].[Cl-].C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CC[NH+]3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 GXFZCDMWGMFGFL-KKXMJGKMSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000017457 Autosomal erythropoietic protoporphyria Diseases 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241001330002 Bambuseae Species 0.000 description 1
- CAHQGWAXKLQREW-UHFFFAOYSA-N Benzal chloride Chemical compound ClC(Cl)C1=CC=CC=C1 CAHQGWAXKLQREW-UHFFFAOYSA-N 0.000 description 1
- 206010008531 Chills Diseases 0.000 description 1
- 241001111317 Chondrodendron tomentosum Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 239000008709 Curare Substances 0.000 description 1
- 208000034423 Delivery Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010021333 Ileus paralytic Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241000751119 Mila <angiosperm> Species 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 206010054808 Peripheral paralysis Diseases 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 241001474791 Proboscis Species 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 208000008630 Sialorrhea Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229960000451 ambenonium Drugs 0.000 description 1
- OMHBPUNFVFNHJK-UHFFFAOYSA-P ambenonium Chemical compound C=1C=CC=C(Cl)C=1C[N+](CC)(CC)CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Cl OMHBPUNFVFNHJK-UHFFFAOYSA-P 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940055075 anticholinesterase parasympathomimetics Drugs 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 201000005340 cerebral meningioma Diseases 0.000 description 1
- 230000003970 cerebral vascular damage Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000009989 contractile response Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000008181 diaphragm contraction Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 201000008220 erythropoietic protoporphyria Diseases 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 208000014337 facial nerve disease Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229960002362 neostigmine Drugs 0.000 description 1
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- LQJARUQXWJSDFL-UHFFFAOYSA-N phenamine Chemical compound CCOC1=CC=C(NC(=O)CN)C=C1 LQJARUQXWJSDFL-UHFFFAOYSA-N 0.000 description 1
- 229950010879 phenamine Drugs 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- GPVVBCKMCIOPMN-UHFFFAOYSA-N quinolin-1-ium;hydroxide Chemical compound O.N1=CC=CC2=CC=CC=C21 GPVVBCKMCIOPMN-UHFFFAOYSA-N 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000004894 snout Anatomy 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 210000001177 vas deferen Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Other In-Based Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP16155182A JPS5955830A (ja) | 1982-09-16 | 1982-09-16 | 末梢神経系統における興奮伝導の刺戟剤としての医薬組成物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP16155182A JPS5955830A (ja) | 1982-09-16 | 1982-09-16 | 末梢神経系統における興奮伝導の刺戟剤としての医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5955830A true JPS5955830A (ja) | 1984-03-31 |
| JPS6335611B2 JPS6335611B2 (enExample) | 1988-07-15 |
Family
ID=15737256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP16155182A Granted JPS5955830A (ja) | 1982-09-16 | 1982-09-16 | 末梢神経系統における興奮伝導の刺戟剤としての医薬組成物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5955830A (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01308259A (ja) * | 1988-01-26 | 1989-12-12 | N I Inst Tekhnol I Bezopasnosti Lekarstvenn Sredstv | ４‐アミノ‐２，３‐二置換‐６，７‐ジヒドロ‐５ｈ‐１‐ピリンジン誘導体 |
| WO1996012495A1 (en) * | 1994-10-24 | 1996-05-02 | Nikken Chemicals Co., Ltd | Percutaneously administrable preparation |
-
1982
- 1982-09-16 JP JP16155182A patent/JPS5955830A/ja active Granted
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01308259A (ja) * | 1988-01-26 | 1989-12-12 | N I Inst Tekhnol I Bezopasnosti Lekarstvenn Sredstv | ４‐アミノ‐２，３‐二置換‐６，７‐ジヒドロ‐５ｈ‐１‐ピリンジン誘導体 |
| WO1996012495A1 (en) * | 1994-10-24 | 1996-05-02 | Nikken Chemicals Co., Ltd | Percutaneously administrable preparation |
| US5869088A (en) * | 1994-10-24 | 1999-02-09 | Nikken Chemicals Co., Ltd | Transdermal administration preparation of a 9-aminocyclopenta (b) quinoline |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6335611B2 (enExample) | 1988-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4550113A (en) | 9-Amino-2,3,5,6,7,8-hexahydro-1H-cyclopenta(b)quinoline monohydrate hydrochloride as stimulant of neuro-muscular transmission of smooth muscles | |
| Stevens | Psychiatric consequences of temporal lobectomy for intractable seizures: a 20–30-year follow-up of 14 cases | |
| CN109748881A (zh) | 胱硫醚-γ-裂合酶(CSE)抑制剂 | |
| RU2451512C2 (ru) | Нейрогенез, опосредованный производным 4-ациламинориридина | |
| RS51302B (sr) | Derivati indolil-3-glioksilne kiseline sa terapeutski vrednim svojstvima | |
| Lehmann | Therapeutic results with chlorpromazine (Largactil) in psychiatric conditions | |
| Strumper et al. | Antidepressants as long-acting local anesthetics | |
| JPS5955830A (ja) | 末梢神経系統における興奮伝導の刺戟剤としての医薬組成物 | |
| Kubo et al. | Cardiovascular response to microinjection of physostigmine and choline into the dorsal medullary site of the rat | |
| Slaughter et al. | New clinical aspects of the analgesic action of morphine | |
| US20020013280A1 (en) | Pharmaceutical composition for preventing and treating sexual dysfunction and vasculargenic disease comprising icariin | |
| TW544311B (en) | Therapeutic or preventive agent for intractable epilepsies | |
| KR100394329B1 (ko) | 성기능장애 및 혈관계질환의 치료용 약제학적 조성물 | |
| Blair | The modern treatment of epilepsy: a critical survey, with special reference to sodium diphenyl hydantoinate and a comparison of its effects with those of other anticonvulsants | |
| US6916845B2 (en) | Method for prevention and treatment of male and female sexual dysfunction | |
| DE3231571C2 (enExample) | ||
| KR20210058586A (ko) | 실데나필 및 rock 저해제를 포함하는 뇌졸중 치료용 약학적 조성물 | |
| RU2224519C2 (ru) | Антиоксидантное и стимулирующее рост нервных клеток средство | |
| GB2125696A (en) | Compositions containing quinoline derivatives | |
| GB1559918A (en) | 3-phenoxypyridine derivative and its production | |
| CN112569237A (zh) | 伊马替尼及其衍生物与尼古丁或其类似物联用或复方在防治尼古丁成瘾与复吸中的应用 | |
| US20250228881A1 (en) | Composition for prevention or treatment of multiple myeloma comprising novel tetracyclic triterpene compound as active ingredient | |
| Mason | The pharmacologic action of lead in organic combination | |
| Birkmayer | The importance of monoamine metabolism for the pathology of the extrapyramidal system | |
| RU2675237C1 (ru) | Соединение (6-{ [(1S)-1(5-фтор-4-оксо-3-фенил-3,4-дигидрохиназолин-2-ил)пропил]амино} -9Н-пурин-9-ил)метилацетат как ингибитор p110δ - дельта-изоформы фосфоинозитид-3-киназы (PI3K), способы его получения (варианты) и применения |